Comparing Cardiol Therapeutics (NASDAQ:CRDL) and IN8bio (NASDAQ:INAB)

IN8bio (NASDAQ:INAB) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for IN8bio and Cardiol Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	0	0	2	0	3.00
Cardiol Therapeutics	0	0	4	1	3.20

IN8bio presently has a consensus price target of $10.00, suggesting a potential upside of 3,181.92%. Cardiol Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 360.53%. Given IN8bio’s higher probable upside, equities research analysts plainly believe IN8bio is more favorable than Cardiol Therapeutics.

Profitability

This table compares IN8bio and Cardiol Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-173.12%	-118.40%
Cardiol Therapeutics	N/A	-118.65%	-85.28%

Earnings & Valuation

This table compares IN8bio and Cardiol Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$30.01 million	($0.83)	-0.37
Cardiol Therapeutics	$60,000.00	2,530.17	-$20.84 million	($0.33)	-5.76

Cardiol Therapeutics has higher revenue and earnings than IN8bio. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

IN8bio has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Insider and Institutional Ownership

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 15.5% of IN8bio shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cardiol Therapeutics beats IN8bio on 9 of the 13 factors compared between the two stocks.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.